secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0001127537-24-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q4 revenue $19.3M (+25% YoY); full-year 2023 revenue $68.7M (+28% YoY)
------------------------------------------------------------------------------

- Record Q4 U.S. revenue of $13.7M (+45% YoY); added 14 new Zephyr Valve treatment centers.
- Gross margin improved to 75% in Q4; full-year gross margin flat at 74%.
- Net loss of $13.9M ($0.36/share) in Q4; full-year net loss $60.8M ($1.60/share).
- Adjusted EBITDA loss narrowed to $39.0M in 2023 from $41.1M in 2022.
- 2024 revenue guidance of $81-84M; expects gross margin 74-75% and OpEx $132-134M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753724000013/0001127537-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753724000013/lung-20240221.htm
  HTML page:      https://secwatch.observer/filing/0001127537-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer